Workflow
1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street
IOVAIovance Biotherapeutics(IOVA) The Motley Fool·2025-03-22 17:56

Core Viewpoint - Iovance Biotherapeutics has innovative cancer therapies but faces challenges in market performance despite regulatory approval of its key therapy, Amtagvi [1][2]. Company Overview - Iovance Biotherapeutics specializes in developing therapies using tumor-infiltrating lymphocytes (TILs) to target cancer cells [3]. - The company’s flagship product, Amtagvi, is a personalized treatment for melanoma that received FDA approval last year [3][4]. Market Performance - The stock has declined by 74% over the past 12 months, trading under 4pershare,whichisclosetoits52−weeklow[2].−Analystshaveabullishoutlook,withpricetargetsrangingfrom4 per share, which is close to its 52-week low [2]. - Analysts have a bullish outlook, with price targets ranging from 6 to 32,andanaveragetargetof32, and an average target of 19.54 [2]. Product Details - Amtagvi takes 34 days to manufacture and is administered in specialized treatment centers, which complicates its rollout [4]. - Iovance reported 164.1millioninrevenuelastyearandhasonlybeguntoaddressthe20,000eligiblemelanomapatientsintheU.S.[5].MarketPotential−Thereareanestimated325,000annualmelanomacasesworldwide,indicatingasignificantmarketopportunityforIovance[6].−Thecompanyisseekingregulatoryapprovalsinadditionalcountries,potentiallyexpandingitspatientbaseby2025[5][8].FutureProjections−IovanceanticipatesproductrevenueforAmtagvitobebetween164.1 million in revenue last year and has only begun to address the 20,000 eligible melanoma patients in the U.S. [5]. Market Potential - There are an estimated 325,000 annual melanoma cases worldwide, indicating a significant market opportunity for Iovance [6]. - The company is seeking regulatory approvals in additional countries, potentially expanding its patient base by 2025 [5][8]. Future Projections - Iovance anticipates product revenue for Amtagvi to be between 450 million and 475millionin2025[9].−Thecompanyhasapipelineofoveradozenprograms,includingtrialsfornon−smallcelllungcancer,whichcouldserveascatalystsforgrowth[10].FinancialOutlook−Iovanceaimstokeepitscashburnunder475 million in 2025 [9]. - The company has a pipeline of over a dozen programs, including trials for non-small cell lung cancer, which could serve as catalysts for growth [10]. Financial Outlook - Iovance aims to keep its cash burn under 300 million for 2025, which is below its projected revenue range [11]. - The company improved its net loss per share from 1.89in2023to1.89 in 2023 to 1.28 in 2024, indicating progress in financial performance [12].